Bausch + Lomb Corporation (NYSE:BLCO) Receives $17.92 Consensus PT from Analysts

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been given an average recommendation of “Hold” by the fourteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $17.9167.

Several analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Bausch + Lomb in a research report on Monday, April 20th. Citigroup set a $19.00 price target on shares of Bausch + Lomb and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Stifel Nicolaus set a $16.00 price target on shares of Bausch + Lomb in a research report on Thursday, February 19th. Finally, HC Wainwright raised their price target on shares of Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd.

Bausch + Lomb Stock Performance

NYSE BLCO opened at $14.89 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.53 and a quick ratio of 0.99. The firm has a market capitalization of $5.32 billion, a price-to-earnings ratio of -24.01, a P/E/G ratio of 0.46 and a beta of 0.58. The company’s fifty day moving average is $15.86 and its two-hundred day moving average is $16.57. Bausch + Lomb has a 52-week low of $11.58 and a 52-week high of $18.92.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted ($0.07) EPS. Equities research analysts forecast that Bausch + Lomb will post 0.82 EPS for the current year.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in Bausch + Lomb by 16.0% in the first quarter. Bank of America Corp DE now owns 65,765 shares of the company’s stock valued at $1,046,000 after acquiring an additional 9,066 shares during the period. Royal Bank of Canada increased its stake in Bausch + Lomb by 67.1% in the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock valued at $58,000 after acquiring an additional 1,468 shares during the period. Whitebox Advisors LLC increased its stake in Bausch + Lomb by 15.8% in the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock valued at $17,519,000 after acquiring an additional 150,641 shares during the period. Sei Investments Co. increased its stake in Bausch + Lomb by 100.0% in the first quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock valued at $2,214,000 after acquiring an additional 69,633 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Bausch + Lomb by 13.2% in the first quarter. Dimensional Fund Advisors LP now owns 85,779 shares of the company’s stock valued at $1,362,000 after acquiring an additional 9,971 shares during the period. 11.07% of the stock is owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.